CRLF2 and acute lymphoblastic leukemia: Currently, ruxolitinib in cotreatment with consolidation chemotherapy is also being tested in the treatment of children with HR CRLF2-rearranged and/or JAK pathway-mutant Ph-like pre-B-ALL (NCT02723994).